Recent discussions highlight significant shortcomings in the treatment of age-related diseases. Commenters express concern over the parallels between software quality issues and challenges in the pharmaceutical industry, suggesting systemic problems may affect both fields. The overwhelming sentiment indicates that current approaches are insufficient and require reevaluation to improve patient outcomes.